KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 89 filers reported holding KALA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,000 | -89.5% | 12,975 | -52.3% | 0.00% | -80.0% |
| Q1 2022 | $38,000 | -42.4% | 27,185 | +7.1% | 0.01% | -28.6% |
| Q3 2021 | $66,000 | -57.7% | 25,375 | +9.5% | 0.01% | -73.1% |
| Q1 2021 | $156,000 | +119.7% | 23,184 | +120.5% | 0.03% | +116.7% |
| Q4 2020 | $71,000 | – | 10,516 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,727,751 | $4,527,000 | 3.67% |
| RA Capital Management | 10,874,613 | $28,491,000 | 0.40% |
| ACT CAPITAL MANAGEMENT, LLC | 190,000 | $498,000 | 0.26% |
| Samsara BioCapital, LLC | 601,162 | $1,575,000 | 0.25% |
| Orbimed Advisors | 3,438,998 | $9,010,000 | 0.10% |
| Towercrest Capital Management | 122,500 | $321,000 | 0.06% |
| Knights of Columbus Asset Advisors LLC | 236,757 | $620,000 | 0.06% |
| Matisse Capital | 56,100 | $147,000 | 0.05% |
| Taylor Wealth Management Partners | 43,990 | $115,000 | 0.04% |
| SYMONS CAPITAL MANAGEMENT INC | 14,346 | $37,000 | 0.02% |